Unimolecular Polypharmacy for Treatment of Diabetes and Obesity

Cell Metabolism

Volumn 24, Issue 1, 2016, Pages 51-62

  Tschöp, Matthias H ^a,b,c   Finan, Brian ^a,b,c   Clemmensen, Christoffer ^a,b,c   Gelfanov, Vasily ^d   Perez Tilve, Diego ^e   Müller, Timo D ^a,b,c   DiMarchi, Richard D ^d  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^d INDIANA UNIVERSITY   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; PEPTIDE HORMONE; PROGLUCAGON; PEPTIDE;

BARIATRIC SURGERY; BODY WEIGHT MANAGEMENT; DIABETES MELLITUS; HUMAN; OBESITY; PERSONALIZED MEDICINE; PHARMACEUTICAL CARE; POLYPHARMACY; PRIORITY JOURNAL; REVIEW; AMINO ACID SEQUENCE; CHEMISTRY; DIABETES MELLITUS, TYPE 2; METABOLISM;

AMINO ACID SEQUENCE; BARIATRIC SURGERY; DIABETES MELLITUS, TYPE 2; GLUCAGON; HUMANS; OBESITY; PEPTIDES; POLYPHARMACY;

EID: 84992316987     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2016.06.021     Document Type: Review

References (94)

1. Adams, T.D., Davidson, L.E., Litwin, S.E., Kolotkin, R.L., LaMonte, M.J., Pendleton, R.C., Strong, M.B., Vinik, R., Wanner, N.A., Hopkins, P.N., et al. Health benefits of gastric bypass surgery after 6 years. JAMA 308 (2012), 1122–1131.
2. Adams, A.C., Halstead, C.A., Hansen, B.C., Irizarry, A.R., Martin, J.A., Myers, S.R., Reynolds, V.L., Smith, H.W., Wroblewski, V.J., Kharitonenkov, A., LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys. PLoS ONE, 8, 2013, e65763.
3. Adan, R.A., Mechanisms underlying current and future anti-obesity drugs. Trends Neurosci. 36 (2013), 133–140.
4. Allison, D.B., Gadde, K.M., Garvey, W.T., Peterson, C.A., Schwiers, M.L., Najarian, T., Tam, P.Y., Troupin, B., Day, W.W., Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 20 (2012), 330–342.
5. Baggio, L.L., Huang, Q., Brown, T.J., Drucker, D.J., Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127 (2004), 546–558.
6. Barnett, A.H., Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus. Postgrad. Med. 125 (2013), 92–100.
7. Bates, S.H., Stearns, W.H., Dundon, T.A., Schubert, M., Tso, A.W., Wang, Y., Banks, A.S., Lavery, H.J., Haq, A.K., Maratos-Flier, E., et al. STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature 421 (2003), 856–859.
8. Berglund, L.M., Lyssenko, V., Ladenvall, C., Kotova, O., Edsfeldt, A., Pilgaard, K., Alkayyali, S., Brøns, C., Forsblom, C., Jonsson, A., et al. Glucose-dependent insulinotropic polypeptide stimulates osteopontin expression in the vasculature via endothelin-1 and CREB. Diabetes 65 (2016), 239–254.
9. Bjerre Knudsen, L., Madsen, L.W., Andersen, S., Almholt, K., de Boer, A.S., Drucker, D.J., Gotfredsen, C., Egerod, F.L., Hegelund, A.C., Jacobsen, H., et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151 (2010), 1473–1486.
10. Buchwald, H., Estok, R., Fahrbach, K., Banel, D., Jensen, M.D., Pories, W.J., Bantle, J.P., Sledge, I., Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am. J. Med. 122 (2009), 248–256.e5.
11. Butler, P.C., Elashoff, M., Elashoff, R., Gale, E.A., A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe?. Diabetes Care 36 (2013), 2118–2125.
12. Campbell, J.E., Drucker, D.J., Islet α cells and glucagon—critical regulators of energy homeostasis. Nat. Rev. Endocrinol. 11 (2015), 329–338.
13. Cegla, J., Troke, R.C., Jones, B., Tharakan, G., Kenkre, J., McCullough, K.A., Lim, C.T., Parvizi, N., Hussein, M., Chambers, E.S., et al. Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake. Diabetes 63 (2014), 3711–3720.
14. Chan, J.L., Mun, E.C., Stoyneva, V., Mantzoros, C.S., Goldfine, A.B., Peptide YY levels are elevated after gastric bypass surgery. Obesity (Silver Spring) 14 (2006), 194–198.
15. Chang, Y.C., Chang, T.J., Jiang, Y.D., Kuo, S.S., Lee, K.C., Chiu, K.C., Chuang, L.M., Association study of the genetic polymorphisms of the transcription factor 7-like 2 (TCF7L2) gene and type 2 diabetes in the Chinese population. Diabetes 56 (2007), 2631–2637.
16. Christensen, R., Kristensen, P.K., Bartels, E.M., Bliddal, H., Astrup, A., Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370 (2007), 1706–1713.
17. Claus, T.H., Pan, C.Q., Buxton, J.M., Yang, L., Reynolds, J.C., Barucci, N., Burns, M., Ortiz, A.A., Roczniak, S., Livingston, J.N., et al. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes. J. Endocrinol. 192 (2007), 371–380.
18. Clemmensen, C., Chabenne, J., Finan, B., Sullivan, L., Fischer, K., Küchler, D., Sehrer, L., Ograjsek, T., Hofmann, S.M., Schriever, S.C., et al. GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. Diabetes 63 (2014), 1422–1427.
19. Connolly, H.M., Crary, J.L., McGoon, M.D., Hensrud, D.D., Edwards, B.S., Edwards, W.D., Schaff, H.V., Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 337 (1997), 581–588.
20. Cummings, D.E., Weigle, D.S., Frayo, R.S., Breen, P.A., Ma, M.K., Dellinger, E.P., Purnell, J.Q., Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N. Engl. J. Med. 346 (2002), 1623–1630.
21. Dakin, C.L., Gunn, I., Small, C.J., Edwards, C.M., Hay, D.L., Smith, D.M., Ghatei, M.A., Bloom, S.R., Oxyntomodulin inhibits food intake in the rat. Endocrinology 142 (2001), 4244–4250.
22. Davidson, I.W., Salter, J.M., Best, C.H., Calorigenic action of glucagon. Nature, 180, 1957, 1124.
23. Davidson, M.H., Hauptman, J., DiGirolamo, M., Foreyt, J.P., Halsted, C.H., Heber, D., Heimburger, D.C., Lucas, C.P., Robbins, D.C., Chung, J., Heymsfield, S.B., Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 281 (1999), 235–242.
24. Davies, M.J., Kela, R., Khunti, K., Liraglutide—overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes Obes. Metab. 13 (2011), 207–220.
25. Day, J.W., Ottaway, N., Patterson, J.T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D.J., Chaudhary, N., et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat. Chem. Biol. 5 (2009), 749–757.
26. Day, J.W., Gelfanov, V., Smiley, D., Carrington, P.E., Eiermann, G., Chicchi, G., Erion, M.D., Gidda, J., Thornberry, N.A., Tschöp, M.H., et al. Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents. Biopolymers 98 (2012), 443–450.
27. Dietrich, M.O., Horvath, T.L., Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons. Nat. Rev. Drug Discov. 11 (2012), 675–691.
28. Duffy, A.M., Hölscher, C., The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease. Neuroscience 228 (2013), 294–300.
29. Elias, C.F., Aschkenasi, C., Lee, C., Kelly, J., Ahima, R.S., Bjorbaek, C., Flier, J.S., Saper, C.B., Elmquist, J.K., Leptin differentially regulates NPY and POMC neurons projecting to the lateral hypothalamic area. Neuron 23 (1999), 775–786.
30. Ettinger, M.P., Littlejohn, T.W., Schwartz, S.L., Weiss, S.R., McIlwain, H.H., Heymsfield, S.B., Bray, G.A., Roberts, W.G., Heyman, E.R., Stambler, N., et al. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA 289 (2003), 1826–1832.
31. Farooqi, I.S., Jebb, S.A., Langmack, G., Lawrence, E., Cheetham, C.H., Prentice, A.M., Hughes, I.A., McCamish, M.A., O'Rahilly, S., Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N. Engl. J. Med. 341 (1999), 879–884.
32. Finan, B., Yang, B., Ottaway, N., Stemmer, K., Müller, T.D., Yi, C.X., Habegger, K., Schriever, S.C., García-Cáceres, C., Kabra, D.G., et al. Targeted estrogen delivery reverses the metabolic syndrome. Nat. Med. 18 (2012), 1847–1856.
33. Finan, B., Ma, T., Ottaway, N., Müller, T.D., Habegger, K.M., Heppner, K.M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci. Transl. Med., 5, 2013, 209ra151.
34. Finan, B., Clemmensen, C., Müller, T.D., Emerging opportunities for the treatment of metabolic diseases: glucagon-like peptide-1 based multi-agonists. Mol. Cell. Endocrinol. 418 (2015), 42–54.
35. Finan, B., Yang, B., Ottaway, N., Smiley, D.L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K.M., Fischer, K., et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat. Med. 21 (2015), 27–36.
36. Finan, B., Müller, T.D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R.D., Tschöp, M.H., Reappraisal of GIP pharmacology for metabolic diseases. Trends Mol. Med. 22 (2016), 359–376.
37. Gaich, G., Chien, J.Y., Fu, H., Glass, L.C., Deeg, M.A., Holland, W.L., Kharitonenkov, A., Bumol, T., Schilske, H.K., Moller, D.E., The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 18 (2013), 333–340.
38. Gao, Q., Mezei, G., Nie, Y., Rao, Y., Choi, C.S., Bechmann, I., Leranth, C., Toran-Allerand, D., Priest, C.A., Roberts, J.L., et al. Anorectic estrogen mimics leptin's effect on the rewiring of melanocortin cells and Stat3 signaling in obese animals. Nat. Med. 13 (2007), 89–94.
39. Gögebakan, Ö., Osterhoff, M.A., Schüler, R., Pivovarova, O., Kruse, M., Seltmann, A.C., Mosig, A.S., Rudovich, N., Nauck, M., Pfeiffer, A.F., GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: a randomised trial. Diabetologia 58 (2015), 1759–1768.
40. Grant, S.F., Thorleifsson, G., Reynisdottir, I., Benediktsson, R., Manolescu, A., Sainz, J., Helgason, A., Stefansson, H., Emilsson, V., Helgadottir, A., et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat. Genet. 38 (2006), 320–323.
41. Greenfield, J.R., Miller, J.W., Keogh, J.M., Henning, E., Satterwhite, J.H., Cameron, G.S., Astruc, B., Mayer, J.P., Brage, S., See, T.C., et al. Modulation of blood pressure by central melanocortinergic pathways. N. Engl. J. Med. 360 (2009), 44–52.
42. Guariguata, L., Whiting, D.R., Hambleton, I., Beagley, J., Linnenkamp, U., Shaw, J.E., Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res. Clin. Pract. 103 (2014), 137–149.
43. Habegger, K.M., Heppner, K.M., Geary, N., Bartness, T.J., DiMarchi, R., Tschöp, M.H., The metabolic actions of glucagon revisited. Nat. Rev. Endocrinol. 6 (2010), 689–697.
44. Habegger, K.M., Kirchner, H., Yi, C.X., Heppner, K.M., Sweeney, D., Ottaway, N., Holland, J., Amburgy, S., Raver, C., Krishna, R., et al. GLP-1R agonism enhances adjustable gastric banding in diet-induced obese rats. Diabetes 62 (2013), 3261–3267.
45. Habegger, K.M., Stemmer, K., Cheng, C., Müller, T.D., Heppner, K.M., Ottaway, N., Holland, J., Hembree, J.L., Smiley, D., Gelfanov, V., et al. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 62 (2013), 1453–1463.
46. Habegger, K.M., Heppner, K.M., Amburgy, S.E., Ottaway, N., Holland, J., Raver, C., Bartley, E., Müller, T.D., Pfluger, P.T., Berger, J., et al. GLP-1R responsiveness predicts individual gastric bypass efficacy on glucose tolerance in rats. Diabetes 63 (2014), 505–513.
47. Halaas, J.L., Gajiwala, K.S., Maffei, M., Cohen, S.L., Chait, B.T., Rabinowitz, D., Lallone, R.L., Burley, S.K., Friedman, J.M., Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269 (1995), 543–546.
48. Hansen, H.H., Barkholt, P., Fabricius, K., Jelsing, J., Terwel, D., Pyke, C., Knudsen, L.B., Vrang, N., The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy. Brain Res. 1634 (2016), 158–170.
49. Heppner, K.M., Habegger, K.M., Day, J., Pfluger, P.T., Perez-Tilve, D., Ward, B., Gelfanov, V., Woods, S.C., DiMarchi, R., Tschöp, M., Glucagon regulation of energy metabolism. Physiol. Behav. 100 (2010), 545–548.
50. Heymsfield, S.B., Greenberg, A.S., Fujioka, K., Dixon, R.M., Kushner, R., Hunt, T., Lubina, J.A., Patane, J., Self, B., Hunt, P., McCamish, M., Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282 (1999), 1568–1575.
51. Hjorth, S.A., Adelhorst, K., Pedersen, B.B., Kirk, O., Schwartz, T.W., Glucagon and glucagon-like peptide 1: selective receptor recognition via distinct peptide epitopes. J. Biol. Chem. 269 (1994), 30121–30124.
52. Højberg, P.V., Vilsbøll, T., Rabøl, R., Knop, F.K., Bache, M., Krarup, T., Holst, J.J., Madsbad, S., Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52 (2009), 199–207.
53. Jansen, P.L., van Werven, J., Aarts, E., Berends, F., Janssen, I., Stoker, J., Schaap, F.G., Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery. Dig. Dis. 29 (2011), 48–51.
54. Ji, C., Xue, G.F., Lijun, C., Feng, P., Li, D., Li, L., Li, G., Hölscher, C., A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF. Brain Res. 1634 (2016), 1–11.
55. Jiménez, A., Casamitjana, R., Viaplana-Masclans, J., Lacy, A., Vidal, J., GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgery. Diabetes Care 36 (2013), 2062–2069.
56. Joel, C.D., Stimulation of metabolism of rat brown adipose tissue by addition of lipolytic hormones in vitro. J. Biol. Chem. 241 (1966), 814–821.
57. Jørgensen, N.B., Dirksen, C., Bojsen-Møller, K.N., Jacobsen, S.H., Worm, D., Hansen, D.L., Kristiansen, V.B., Naver, L., Madsbad, S., Holst, J.J., Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes 62 (2013), 3044–3052.
58. Kharitonenkov, A., Wroblewski, V.J., Koester, A., Chen, Y.F., Clutinger, C.K., Tigno, X.T., Hansen, B.C., Shanafelt, A.B., Etgen, G.J., The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148 (2007), 774–781.
59. Korner, J., Bessler, M., Inabnet, W., Taveras, C., Holst, J.J., Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg. Obes. Relat. Dis. 3 (2007), 597–601.
60. Kuroshima, A., Yahata, T., Thermogenic responses of brown adipocytes to noradrenaline and glucagon in heat-acclimated and cold-acclimated rats. Jpn. J. Physiol. 29 (1979), 683–690.
61. Lao, J., Hansen, B.C., DiMarchi, R., Pocai, A., Effect of GLP1R/GCGR dual agonist in monkeys. Diabetes, 62(Suppl. 1), 2013, A257.
62. Liu, J., Lee, J., Salazar Hernandez, M.A., Mazitschek, R., Ozcan, U., Treatment of obesity with celastrol. Cell 161 (2015), 999–1011.
63. Locke, A.E., Kahali, B., Berndt, S.I., Justice, A.E., Pers, T.H., Day, F.R., Powell, C., Vedantam, S., Buchkovich, M.L., Yang, J., et al. LifeLines Cohort Study ADIPOGen Consortium AGEN-BMI Working Group CARDIOGRAMplusC4D Consortium CKDGen Consortium GLGC ICBP MAGIC Investigators MuTHER Consortium MIGen Consortium PAGE Consortium ReproGen Consortium GENIE Consortium, International Endogene Consortium. Genetic studies of body mass index yield new insights for obesity biology. Nature 518 (2015), 197–206.
64. Ma, X., Xu, L., Alberobello, A.T., Gavrilova, O., Bagattin, A., Skarulis, M., Liu, J., Finkel, T., Mueller, E., Celastrol protects against obesity and metabolic dysfunction through activation of a HSF1-PGC1α transcriptional axis. Cell Metab. 22 (2015), 695–708.
65. Marino, A.B., Cole, S.W., Nuzum, D.S., Alternative dosing strategies for liraglutide in patients with type 2 diabetes mellitus. Am. J. Health Syst. Pharm. 71 (2014), 223–226.
66. McClean, P.L., Irwin, N., Cassidy, R.S., Holst, J.J., Gault, V.A., Flatt, P.R., GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am. J. Physiol. Endocrinol. Metab. 293 (2007), E1746–E1755.
67. Mentis, N., Vardarli, I., Köthe, L.D., Holst, J.J., Deacon, C.F., Theodorakis, M., Meier, J.J., Nauck, M.A., GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes 60 (2011), 1270–1276.
68. Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 8 (2002), 738–742.
69. Müller, W.A., Faloona, G.R., Aguilar-Parada, E., Unger, R.H., Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N. Engl. J. Med. 283 (1970), 109–115.
70. Näslund, E., Backman, L., Holst, J.J., Theodorsson, E., Hellström, P.M., Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obes. Surg. 8 (1998), 253–260.
71. Nauck, M.A., Heimesaat, M.M., Orskov, C., Holst, J.J., Ebert, R., Creutzfeldt, W., Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91 (1993), 301–307.
72. Pan, C.Q., Buxton, J.M., Yung, S.L., Tom, I., Yang, L., Chen, H., MacDougall, M., Bell, A., Claus, T.H., Clairmont, K.B., Whelan, J.P., Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist. J. Biol. Chem. 281 (2006), 12506–12515.
73. Patti, M.E., Houten, S.M., Bianco, A.C., Bernier, R., Larsen, P.R., Holst, J.J., Badman, M.K., Maratos-Flier, E., Mun, E.C., Pihlajamaki, J., et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) 17 (2009), 1671–1677.
74. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D.C., le Roux, C.W., Violante Ortiz, R., Jensen, C.B., Wilding, J.P., SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N. Engl. J. Med. 373 (2015), 11–22.
75. Plodkowski, R.A., Nguyen, Q., Sundaram, U., Nguyen, L., Chau, D.L., St Jeor, S., Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. Expert Opin. Pharmacother. 10 (2009), 1069–1081.
76. Pocai, A., Carrington, P.E., Adams, J.R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M.E., Jiang, G., et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58 (2009), 2258–2266.
77. Rodgers, R.J., Tschöp, M.H., Wilding, J.P., Anti-obesity drugs: past, present and future. Dis. Model. Mech. 5 (2012), 621–626.
78. Ryan, K.K., Tremaroli, V., Clemmensen, C., Kovatcheva-Datchary, P., Myronovych, A., Karns, R., Wilson-Pérez, H.E., Sandoval, D.A., Kohli, R., Bäckhed, F., Seeley, R.J., FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 509 (2014), 183–188.
79. Salehi, M., D'Alessio, D.A., Effects of glucagon like peptide-1 to mediate glycemic effects of weight loss surgery. Rev. Endocr. Metab. Disord. 15 (2014), 171–179.
80. Salehi, M., Prigeon, R.L., D'Alessio, D.A., Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes 60 (2011), 2308–2314.
81. Scheen, A.J., Paquot, N., Obesity. A new paradigm for treating obesity and diabetes mellitus. Nat. Rev. Endocrinol. 11 (2015), 196–198.
82. Scheen, A.J., Van Gaal, L.F., Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol. 2 (2014), 911–922.
83. Schwartz, M.W., Seeley, R.J., Woods, S.C., Weigle, D.S., Campfield, L.A., Burn, P., Baskin, D.G., Leptin increases hypothalamic pro-opiomelanocortin mRNA expression in the rostral arcuate nucleus. Diabetes 46 (1997), 2119–2123.
84. Schwartz, L.K., O'Keefe, S.J., Fujioka, K., Gabe, S.M., Lamprecht, G., Pape, U.F., Li, B., Youssef, N.N., Jeppesen, P.B., Long-term teduglutide for the treatment of patients with intestinal failure associated with short bowel syndrome. Clin. Transl. Gastroenterol., 7, 2016, e142.
85. Seeley, R.J., Chambers, A.P., Sandoval, D.A., The role of gut adaptation in the potent effects of multiple bariatric surgeries on obesity and diabetes. Cell Metab. 21 (2015), 369–378.
86. Smith, S.R., Weissman, N.J., Anderson, C.M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., Shanahan, W.R., Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N. Engl. J. Med. 363 (2010), 245–256.
87. Sparre-Ulrich, A.H., Hansen, L.S., Svendsen, B., Christensen, M., Knop, F.K., Hartmann, B., Holst, J.J., Rosenkilde, M.M., Species-specific action of (Pro3)GIP—a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors. Br. J. Pharmacol. 173 (2016), 27–38.
88. Stefater, M.A., Wilson-Pérez, H.E., Chambers, A.P., Sandoval, D.A., Seeley, R.J., All bariatric surgeries are not created equal: insights from mechanistic comparisons. Endocr. Rev. 33 (2012), 595–622.
89. Talukdar, S., Zhou, Y., Li, D., Rossulek, M., Dong, J., Somayaji, V., Weng, Y., Clark, R., Lanba, A., Owen, B.M., et al. A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab. 23 (2016), 427–440.
90. Tan, T.M., Field, B.C., McCullough, K.A., Troke, R.C., Chambers, E.S., Salem, V., Gonzalez Maffe, J., Baynes, K.C., De Silva, A., Viardot, A., et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 62 (2013), 1131–1138.
91. Tiano, J.P., Delghingaro-Augusto, V., Le May, C., Liu, S., Kaw, M.K., Khuder, S.S., Latour, M.G., Bhatt, S.A., Korach, K.S., Najjar, S.M., et al. Estrogen receptor activation reduces lipid synthesis in pancreatic islets and prevents β cell failure in rodent models of type 2 diabetes. J. Clin. Invest. 121 (2011), 3331–3342.
92. Tschöp, M., Smiley, D.L., Heiman, M.L., Ghrelin induces adiposity in rodents. Nature 407 (2000), 908–913.
93. Vilsbøll, T., Christensen, M., Junker, A.E., Knop, F.K., Gluud, L.L., Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ, 344, 2012, d7771.
94. Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., Friedman, J.M., Positional cloning of the mouse obese gene and its human homologue. Nature 372 (1994), 425–432.